Journal
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
Volume 12, Issue 4, Pages 350-360Publisher
WILEY
DOI: 10.1111/cts.12616
Keywords
-
Categories
Funding
- National Institutes of Health [T32 GM007750, TL1 TR000422, P01 DA032507]
- Eunice Kennedy Shriver National Institute of Child Health and Human Development [K24 HD082231]
- American Foundation for Pharmaceutical Education Pre-Doctoral Award in Pharmaceutical Sciences
Ask authors/readers for more resources
All-trans-retinoic acid (atRA) downregulates cytochrome P450 (CYP)2D6 in several model systems. The aim of this study was to determine whether all active retinoids downregulate CYP2D6 and whether in vitro downregulation translates to in vivo drug-drug interactions (DDIs). The retinoids atRA, 13cisRA, and 4-oxo-13cisRA all decreased CYP2D6 mRNA in human hepatocytes in a concentration-dependent manner. The in vitro data predicted similar to 50% decrease in CYP2D6 activity in humans after dosing with 13cisRA. However, the geometric mean area under plasma concentration-time curve (AUC) ratio for dextromethorphan between treatment and control was 0.822, indicating a weak induction of dextromethorphan clearance following 13cisRA treatment. Similarly, in mice treatment with 4-oxo-13cisRA-induced mRNA expression of multiple mouse Cyp2d genes. In comparison, a weak induction of CYP3A4 in human hepatocytes translated to a weak in vivo induction of CYP3A4. These data suggest that in vitro CYP downregulation may not translate to in vivo DDIs, and better understanding of the mechanisms of CYP downregulation is needed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available